• Chinese scientists to pioneer first human CRISPR trial

    Nature News & Comment | Gene-editing technique to treat lung cancer is due to be tested in people in August. Sichuan University's West China Hospital in Chengdu plans to inject lung cancer patients with cells modified using the CRISPR-Cas9 gene-editing technique. The clinical trial received ethical approval from the hospital July 6.

    Jul 22, 2016

  • Bioz Launches Life Sciences Search Engine

    Bio-IT World | Bioz, Inc. came out of stealth today with the introduction of a search engine for life science experimentation. The company, started by Stanford research scientist Karin Lachmi and serial entrepreneur Daniel Levitt, also announced $3 million in seed funding, led by 5AM Ventures.

    Jul 20, 2016

  • The Seven Bridges CGC: Boon for Bioinformatics, Success for a Startup

    Bio-IT World It's been a busy two years for Seven Bridges. In May 2014, Seven Bridges was introducing its open source cancer informatics pipeline: open source algorithms running on the proprietary Seven Bridges cloud infrastructure. Less than six months later, the company was awarded one of three National Cancer Institute Cloud Pilot contracts.

    Jul 19, 2016

  • Systems Toxicology Computational Challenge Results Announced

    Bio-IT World | The Systems Toxicology Computational Challenge results have been announced from the fourth challenge launched by sbv IMPROVER, an international scientific crowdsourcing initiative.

    Jul 18, 2016

  • Appistry’s Vision for Clinical Lab Analysis

    Bio-IT World | Appistry launches managed services for clinical sequencing, incorporating GenomePilot, and covering the entire pipeline from when data comes off the sequencers to results analysis.

    Jul 14, 2016

  • With new owner the hated impact factor is overdue for change

    STAT | The impact factor is a poor measure of a journal's quality, and academics say it should either be overhauled or done away with entirely.

    Jul 14, 2016

  • Wellcome Trust launches open-access publishing venture

    Nature News & Comment | Wellcome Open Research is meant to allow Wellcome grant recipients to publish their findings more quickly. The charity hopes other funders will follow a similar model. Management of the venture will be contracted to F1000Research.

    Jul 13, 2016

  • Genomic Medicine Training, New Storage Options, Food Allergy Science

    Bio-IT World | News and product launches from around the Bio-IT landscape include a postdoctoral fellowship in genomics medicine in Alabama, a synthetic biology partnership, new Lustre storage, and the Broad's food allergy science institute.

    Jul 12, 2016

  • A Drug For Postpartum Depression? Sage Passes Early Test With Experimental Treatment

    Forbes | Encouraging news is out today for the treatment of severe postpartum depression. Sage Therapeutics, a biotech company in Cambridge, Mass., reported that its experimental drug was able to relieve severe symptoms of postpartum depression for 70% of patients within a few days, and keep them in remission for a month.

    Jul 12, 2016

  • Intel's Cancer Cloud: Complementing NCI Collaboration

    Bio-IT World | Intel may have missed out on a major government grant, but that hasn't stopped it from developing a collaborative cloud for genomicists and bioinformaticians that it wanted to build all along.

    Jul 11, 2016

  • IT spending will shrink worldwide due to Brexit Gartner predicts

    Computerworld | Britain's vote to exit the European Union will depress global IT spending, according to Gartner analyst John-David Lovelock.

    Jul 8, 2016

  • Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths

    Forbes | Three patients have died in a closely watched study of using genetically engineered white blood cells to treat adult leukemia patients, forcing the trial to be put on hold. The news is a blow for Juno Therapeutics, the biotechnology startup valued at $4.3 billion.

    Jul 8, 2016

  • Obama Seeks To Make Mark On Genetic Medicine

    Forbes | After a few weeks of hype around the Obama administration's efforts to speed cancer research, officials tonight announced plans to kickstart efforts around the president's Precision Medicine Initiative.

    Jul 7, 2016

  • Cloud Adoption Numbers Are All Over the Map

    Fortune | Johnson & Johnson turned off its last mainframe and plans to move 85% of its software to the cloud. Is it mainstream or an outlier?

    Jul 7, 2016

  • Pfizer Might Buy Bind Therapeutics From Bankruptcy for $20M

    Xconomy | Bind Therapeutics and its treatment for treatment for non-small cell lung cancer may soon be owned by one-time partner Pfizer. Bind, which filed for Chapter 11 bankruptcy in May asked the court to approve a bid from Pfizer on July 1.

    Jul 6, 2016

  • Owning Your Data: The Genos Model

    Bio-IT World | Consumer genomics startup, Genos, is expanding its beta program and inviting Bio-IT World readers to sequence their whole exome at CLIA-certified 75x coverage for $399.

    Jul 5, 2016

  • Building Amgen’s RWD Platform

    Bio-IT World | Best Practices Amgen built a Real World Data platform to provide an enterprise-wide capability to better access and analyze available claims, electronic health records (EHRs), and cohort data, and address questions across the clinical and health IT development lifecycle.

    Jul 1, 2016

  • PrecisionFDA Announces Truth Challenge Winners

    Bio-IT World  PrecisionFDA announced the results of its Truth Challenge today. Entries from Verily Life Sciences, Kinghorn Center for Clinical Genomics, and Sanofi-Genzyme won top recognition. In addition to the winners, DNAnexus, Roche, Real Time Genomics, Sentieon, Qunitiles, Macrogen, the Broad Institute, and others participated.

    Jun 29, 2016

  • New Investments, Projects Spur Moonshot Program Forward

    Bio-IT World The Cancer Moonshot Summit today served as a platform for many announcements from both the public and private sectors on ways to advance the Moonshot’s goals.

    Jun 29, 2016

  • Pfizer plans $350M China biotech plant

    USA TODAY | U.S. drug-making giant Pfizer plans to invest roughly $350 to develop a biotechnology center in China, increasing the company's footprint in the world's second-largest pharmaceutical market, the firm said Monday.

    Jun 28, 2016